Ernexia Therapeutics ERNA-101 Selected for Presentation at Cancer Therapeutics Meeting
Preclinical data for Ernexa Therapeutics' ERNA-101, highlighting its potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade, will be presented on October 6, 2026, at MD Anderson Cancer Center.